William Blair Initiates Coverage of Illumina with 'Outperform' Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair said today it has initiated coverage of Illumina's stock, giving it an "outperform" rating.

It also gave San Diego-based Illumina an "aggressive growth" company profile. Amanda Murphy, an analyst at William Blair, estimated a $1.06 earnings per share price for 2010, a $1.46 EPS for 2011, and a $1.93 EPS for 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.